Nanjing Norman was founded in 2008 and has more than 500 employees. It is a national high-tech enterprise in the medical industry and a specialized and new "little giant" enterprise. In recent years, it has successively won the titles of "Jiangsu Provincial Engineering Technology Center" and "Jiangsu Provincial Engineering Technology Center", "Jiangsu Province Science and Technology Progress Award", "Nanjing Unicorn Cultivation" and other honors, and was approved to become the employment internship base of Nanjing University. After years of investment, the company has developed into one of the few companies in the industry with the capabilities of R&D, production and sales of raw materials, reagents and automated medical instruments. At the end of 2022, the company has authorized 140 intellectual property rights.

In terms of raw materials, it can independently develop and produce antigens, antibodies, magnetic beads and other products, and has an SPF-grade animal room. Among them, the PCT (procalcitonin) antibody broke through the technical blockade of Brahms in Germany and obtained the only patent authorization in the world. It has laid a solid foundation for the company's product layout and development, and formed a series of product sequences with independent intellectual property rights.

In terms of instruments, the company has the world's original 7-minute rapid chemiluminescence testing technology, which breaks through the whole blood testing technology. The testing time is greatly advanced, which can save valuable treatment time for patients. Some projects can realize peripheral blood testing, which is especially suitable for use in hospitals with a large number of peripheral blood samples, such as maternal and children's hospitals.

In terms of reagents, the company has a complete range of testing projects, covering more than 100 types of chemiluminescence diagnostic projects such as tumors, infections, inflammation, cardiovascular, diabetes, thyroid, gonads, metabolism, autoimmunity, kidneys, infectious diseases, and drug testing.

In terms of the market, the coverage of domestic tertiary hospitals is about 30%, and about 180 products have obtained EU CE certification and are exported to more than a dozen countries including Germany, Italy, and Romania.

Since its establishment, the company has always adhered to the concept of "R&D determines the future, focus determines success", and its R&D investment ratio ranks among the best in the industry. The number of R&D technical teams accounts for more than 30%. The leading talents in core R&D positions are all PhDs from well-known universities, and their majors cover immunology, biochemistry, molecular biology, optical engineering and other research directions.

Norman Biotech adheres to the core value of "customer first" and takes "providing richer and more complete testing solutions for human health" as its mission. At the same time, with "self-driven and introspective" talents as the foundation, technological innovation as the vitality, and the capital market as the basis, we will build the "Normanbio" brand, seek a century-old foundation, become an innovative leader in the field of outpatient and emergency testing, and promote the development of the testing industry and make more contributions to human health.